Alterity Therapeutics (ATHE) Receivables - Other (2021 - 2023)
Alterity Therapeutics (ATHE) posted quarterly Receivables - Other of $65229.0 for Q2 2023, down 95.8% quarter-over-quarter from $1.6 million in Q4 2021.
Alterity Therapeutics (ATHE) Receivables - Other (2021 - 2023) Analysis & Trends
Alterity Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at $65229.0 for Q2 2023.
- In Q2 2023, Receivables - Other changed N/A year-over-year to $65229.0; the TTM figure through Jun 2023 stood at $65229.0 (changed N/A YoY), while the FY2021 annual figure was $79576.0, changed N/A from the prior year.
- Receivables - Other for Q2 2023 stood at $65229.0, down from $1.6 million in the prior quarter.
- The five-year high for Receivables - Other was $1.6 million in Q4 2021, with the low at $65229.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - |
| 10 | Alterity Therapeutics | 48.83 Mn | 16.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 65,229.00 |
| Jun 30, 2023 | 65,229.00 |
| Dec 31, 2021 | 1.55 Mn |
| Dec 31, 2021 | 1.55 Mn |
| Jun 30, 2021 | 79,575.96 |
| Jun 30, 2021 | 79,575.96 |